Figure 2From: Epratuzumab (humanised anti-CD22 antibody) in primary Sjögren's syndrome: an open-label phase I/II studyImprovement rates in individual efficacy parameters. The improvement rate is based on achieving an improvement of at least 20% from baseline. ESR, erythrocyte sedimentation rate; IgG, immunoglobulin G; VAS, visual analogue scale.Back to article page